pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
IONIS PHARMACEUTICALS INC ($IONS) · news · pharmadog
← back to IONIS PHARMACEUTICALS INC
News mentioning $IONS
68
stories
Aug 28, 26
AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond
fiercebiotech
Aug 28, 26
STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
stat
Aug 28, 26
#ESC26: Trial failure clouds future of AstraZeneca’s heart disease gene silencer
endpoints
Aug 27, 26
STAT+: Alnylam’s heart drug troubles take center stage at a cardiology conference
stat
Aug 24, 26
FDA extends review of Capricor cell therapy; Pain drug startup to go public
biopharma dive
Aug 17, 26
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
Aug 17, 26
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
Aug 12, 26
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
biospace
Aug 10, 26
Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
biospace
Aug 7, 26
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
biopharma dive
Aug 7, 26
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
biospace
Aug 3, 26
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
Jul 31, 26
Ionis' top scientist Frank Bennett to retire; Recursion selects its first AI chief
endpoints
Jul 30, 26
Alnylam plunges as earnings deliver ‘one-two punch’
biopharma dive
Jul 30, 26
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
Jul 30, 26
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
Jul 29, 26
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
Jul 29, 26
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
Jul 27, 26
RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC
fiercebiotech
Jul 27, 26
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
Jul 27, 26
STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease
stat
Jul 23, 26
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 22, 26
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
biopharma dive
Jul 22, 26
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
biospace
Jul 14, 26
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
biopharma dive
Jul 9, 26
AstraZeneca, Ionis drug fails big heart disease study in major setback
biopharma dive
Jul 9, 26
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
stat
Jul 9, 26
Updated: AstraZeneca sinks on unexpected heart drug trial failure
endpoints
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 18, 26
Kardigan extends biotech’s streak of big IPOs with $400M haul
biopharma dive
← prev
page 2 of 3
next →
